FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Dreicer

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Ning Zhou; alex almasan; Robert Dreicer; Jeffrey A Ecsedy; Daniel Lindner; Maria C Mir; Yvonne Parker; Kamini Singh; Bin T Teh; Zhongfa Zhang; Donna E Hansel
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Cora N Sternberg; Dan Theodorescu; David J Vaughn; Dean F Bajorin; Joaquim Bellmunt; Robert Dreicer; Matthew D Galsky; Daniel J George; Matthew I Milowsky; Arlene Siefker-Radtke; Mark S Soloway; Guru Sonpavde; Walter M Stadler; David I Quinn
ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
Matthew M Cooney; Joseph Bokar; Robert Dreicer; Joseph Gibbons; Smitha Krishnamurthi; Anne Ness; Charles Nock; Scot C Remick; Mary Beth Rodal; Afshin Dowlati
Phase I trial of pomalidomide given for patients with advanced solid tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Dreicer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ning Zhou; alex almasan; Robert Dreicer; Jeffrey A Ecsedy; Daniel Lindner; Maria C Mir; Yvonne Parker; Kamini Singh; Bin T Teh; Zhongfa Zhang; Donna E Hansel
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(7):1717-28.
2013: Cora N Sternberg; Dan Theodorescu; David J Vaughn; Dean F Bajorin; Joaquim Bellmunt; Robert Dreicer; Matthew D Galsky; Daniel J George; Matthew I Milowsky; Arlene Siefker-Radtke; Mark S Soloway; Guru Sonpavde; Walter M Stadler; David I Quinn
ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
European urology 2013;63(1):58-66.
2012: Matthew M Cooney; Joseph Bokar; Robert Dreicer; Joseph Gibbons; Smitha Krishnamurthi; Anne Ness; Charles Nock; Scot C Remick; Mary Beth Rodal; Afshin Dowlati
Phase I trial of pomalidomide given for patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2012;70(5):755-61.
2012: Robert Dreicer
Systemic therapy for advanced adrenal cancer.
Journal of surgical oncology 2012;106(5):643-6.
2012: Pierre L Triozzi; Susan Achberger; Wayne Aldrich; Paul Elson; Jorge Garcia; Robert Dreicer
Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(7):587-94.
2012: Sarmad Sadeghi; Laura S Wood; Laurence Albiges; Shari L Black; Robert Dreicer; Bernard J Escudier; Jorge A Garcia; Timothy Gilligan; Brian I Rini
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.
Cancer 2012;118(13):3277-82.
2012: Brian I Rini; Mohammed Salem; Shetal Shah; Andrew Stephenson; Laura Wood; Robert Dreicer; Paul Elson; Amr Fergany; Jorge Garcia; Michael Gong; Jihad Kaouk; Eric Klein; Venkatesh Krishnamurthi; John C Rabets; Steven Campbell
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.
The Journal of urology 2012;187(5):1548-54.
2012: Jenny J Kim; Brian I Rini; Susan A J Vaziri; Robert Wirka; Robert Dreicer; Paul Elson; Mahrukh K Ganapathi; Jorge A Garcia; Ram Ganapathi
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Cancer 2012;118(7):1946-54.
2012: Robert Dreicer
The future of drug development in urothelial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):473-5.
2012: Matthew D Galsky; William K Oh; R Petrioli; B J Roth; Joaquim Bellmunt; G J Chen; L Dogliotti; Robert Dreicer; Guru Sonpavde
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(2):406-10.
2012: Robert Dreicer
Sequencing of therapies in advanced prostate cancer.
Oncology (Williston Park, N.Y.) 2012;26(1):82, 84.
2011: Robert Dreicer; Jorge Garcia; Maha Hussain; Marek Kania; Brian Rini; Bradley Somer; Sandy Srinivas; Nicholas Vogelzang; Yan D Zhao; Derek Raghavan
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.
Investigational new drugs 2011;29(6):1441-8.
2011: Robert Dreicer; Judd W Moul
New data, new paradigms for treating patients with prostate cancer. Conclusion.
Urology 2011;78(5 Suppl):S499.
2011: Robert Dreicer; David G McLeod; Dean F Bajorin; Daniel P Petrylak; Judd W Moul
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.
Urology 2011;78(5 Suppl):S494-8.
2011: Judd W Moul; Mack Roach; Christopher P Evans; Leonard G Gomella; Robert Dreicer
Traditional approaches to androgen deprivation therapy.
Urology 2011;78(5 Suppl):S485-93.
2011: Robert Dreicer; Martin Gleave; Adam S Kibel; J Brantley Thrasher; Judd W Moul
Targeting the androgen receptor--theory and practice.
Urology 2011;78(5 Suppl):S482-4.
2011: Judd W Moul; Mack Roach; Adam S Kibel; Robert Dreicer
Indications and practice with androgen deprivation therapy.
Urology 2011;78(5 Suppl):S478-81.
2011: Judd W Moul; Robert Dreicer
Focusing on testosterone.
Urology 2011;78(5 Suppl):S476-7.
2011: Judd W Moul; Robert Dreicer
New data, new paradigms for treating patients with prostate cancer: introduction.
Urology 2011;78(5 Suppl):S475.
2011: Anita Schwandt; Pierre Triozzi; Jeanie Wyckhouse; Ming Zhou; Robert Dreicer; Paul Elson; James H Finke; Jorge A Garcia; Joanna Ireland; Brian I Rini
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.
Journal of clinical immunology 2011;31(4):690-8.
2011: Franklin M Chu; Joel Picus; Paula M Fracasso; Robert Dreicer; Zhihui Lang; Brenda Foster
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
Investigational new drugs 2011;29(4):674-9.
2011: Matthew D Galsky; Noah M Hahn; Thomas Hutson; William K Oh; Jonathan Rosenberg; Guru Sonpavde; Cora N Sternberg; Nicholas Vogelzang; Dean F Bajorin; Robert Dreicer; Joaquim Bellmunt
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(17):2432-8.
2011: John M Fitzpatrick; Joaquim Bellmunt; Robert Dreicer; Neil E Fleshner; Christopher J Logothetis; Judd W Moul; Bertrand Tombal; Alexandre Zlotta
Maximizing outcomes in genitourinary cancers across the treatment continuum.
BJU international 2011;107 Suppl 2():1-12.
2011: Naveen S Basappa; Paul Elson; Ali-Reza Golshayan; Laura Wood; Jorge A Garcia; Robert Dreicer; Brian I Rini
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
Cancer 2011;117(6):1183-9.
2011: Jorge A Garcia; Robert Dreicer
Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Oncology (Williston Park, N.Y.) 2011;25(3):242-9.
2011: Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora Sternberg; Dean F Bajorin; Joaquim Bellmunt
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.
The lancet oncology 2011;12(3):211-4.
2011: Jorge A Garcia; Thomas E Hutson; Dale Shepard; Paul Elson; Robert Dreicer
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Cancer 2011;117(4):752-7.
2011: Jose A Karam; Brian I Rini; Leticia Varella; Jorge A Garcia; Robert Dreicer; Toni K Choueiri; Eric Jonasch; Surena F Matin; Steven C Campbell; Christopher G Wood; Nizar M Tannir
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
The Journal of urology 2011;185(2):439-44.
2011: Jorge A Garcia; Tarek Mekhail; Paul Elson; Pierre L Triozzi; Cheryl Nemec; Robert Dreicer; Ronald M Bukowski; Brian I Rini
Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.
BJU international 2011;107(4):562-70.
2011: William R Schelman; Glenn Liu; George Wilding; Thomas Morris; De Phung; Robert Dreicer
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
Investigational new drugs 2011;29(1):118-25.
2010: Jorge A Garcia; Thomas E Hutson; Paul Elson; C Lance Cowey; Timothy Gilligan; Cheryl Nemec; Robert Dreicer; Ronald M Bukowski; Brian I Rini
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Cancer 2010;116(23):5383-90.
2010: Juan Barbastefano; Jorge A Garcia; Paul Elson; Laura S Wood; Brian R Lane; Robert Dreicer; Steven C Campbell; Brian I Rini
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
BJU international 2010;106(9):1266-9.
2010: Robert Dreicer
Androgen deprivation therapy in patients with advanced prostate cancer.
The journal of supportive oncology 2010;8(5):209-11.
2010: Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
The New England journal of medicine 2010;363(5):411-22.
2010: Dale R Shepard; Robert Dreicer
Zibotentan for the treatment of castrate-resistant prostate cancer.
Expert opinion on investigational drugs 2010;19(7):899-908.
2010: Brian R Lane; Armine K Smith; Benjamin T Larson; Michael C Gong; Steven C Campbell; Derek Raghavan; Robert Dreicer; Donna E Hansel; Andrew J Stephenson
Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy.
Cancer 2010;116(12):2967-73.
2010: Brian I Rini; Jorge A Garcia; Matthew M Cooney; Paul Elson; Allison Tyler; Kristi Beatty; Joseph Bokar; Percy Ivy; Helen X Chen; Afshin Dowlati; Robert Dreicer
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(17):e284-5; author reply e286-7.
2010: Roberto Pili; Mark A Rosenthal; Paul N Mainwaring; Guy Van Hazel; Sandy Srinivas; Robert Dreicer; SANJAY GOEL; Joseph Leach; Shirley Wong; Peter Clingan
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(10):2906-14.
2009: Maha Hussain; David P Wood Jr; Dean F Bajorin; Bernard H Bochner; Robert Dreicer; Donald L Lamm; Michael A O'Donnell; Arlene O Siefker-Radtke; Dan Theodorescu; Colin P Dinney
Bladder cancer: narrowing the gap between evidence and practice.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5680-4.
2009: Brian I Rini; Jorge A Garcia; Matthew M Cooney; Paul Elson; Allison Tyler; Kristi Beatty; Joseph Bokar; Tarek Mekhail; Ronald M Bukowski; G Thomas Budd; Pierre L Triozzi; Ernest Borden; Percy Ivy; Helen X Chen; Afshin Dolwati; Robert Dreicer
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6277-83.
2009: Robert Dreicer
Second-line chemotherapy for advanced urothelial cancer: because we should or because we can?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4444-5.
2009: Robert Dreicer; Hailun Li; Mark Stein; Robert DiPaola; Michael Eleff; Bruce J Roth; George Wilding
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.
Cancer 2009;115(18):4090-5.
2009: Robert Dreicer; W M Stadler; F R Ahmann; T Whiteside; N Bizouarne; B Acres; J-M Limacher; P Squiban; A Pantuck
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
Investigational new drugs 2009;27(4):379-86.
2009: D R Shepard; Robert Dreicer; J Garcia; Paul Elson; Cristina Magi-Galluzzi; D Raghavan; A J Stephenson; Eric A Klein
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
The Journal of urology 2009;181(4):1672-7; discussion 1677.
2009: Jennifer S Ko; Arnold H Zea; Brian I Rini; Joanna L Ireland; Paul Elson; Peter Cohen; Ali-Reza Golshayan; Patricia Rayman; Laura Wood; Jorge Garcia; Robert Dreicer; Ronald Bukowski; James H Finke
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(6):2148-57.
2009: Christopher J Weight; Jorge A Garcia; Donna E Hansel; Amr Fergany; Steven C Campbell; Michael C Gong; J Stephen Jones; Eric A Klein; Robert Dreicer; Andrew J Stephenson
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
Cancer 2009;115(4):792-9.
2009: Anil A Thomas; Brian I Rini; Brian R Lane; Jorge Garcia; Robert Dreicer; Eric A Klein; Andrew C Novick; Steven C Campbell
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
The Journal of urology 2009;181(2):518-23; discussion 523.
2009: Anita Schwandt; Laura S Wood; Brian Rini; Robert Dreicer
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.
OncoTargets and therapy 2009;2():51-61.
2008: Ila Tamaskar; Tarek Mekhail; Robert Dreicer; Thomas Olencki; S Roman; Paul Elson; Ronald M Bukowski
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
Investigational new drugs 2008;26(6):553-9.
2008: James H Finke; Brian I Rini; Joanna Ireland; Patricia Rayman; Amy Richmond; Ali-Reza Golshayan; Laura Wood; Paul Elson; Jorge Garcia; Robert Dreicer; Ronald Bukowski
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6674-82.
2008: Brian I Rini; Toni K Choueiri; Paul Elson; Mohamad K Khasawneh; Claudiu Cotta; Jaya Unnithan; Laura Wood; Tarek Mekhail; Jorge Garcia; Robert Dreicer; Ronald M Bukowski
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Cancer 2008;113(6):1309-14.
2008: Robert Dreicer
Advanced bladder cancer: so many drugs, so little progress : what's wrong with this picture?
Cancer 2008;113(6):1275-7.
2008: Saby George; Robert Dreicer; Jessie J L Au; Tong Shen; Brian I Rini; Susan Roman; Matthew M Cooney; Tarek Mekhail; Paul Elson; Guillaume M Wientjes; Ram Ganapathi; Ronald M Bukowski
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
Clinical genitourinary cancer 2008;6(2):79-85.
2008: Eric A Klein; Andrew J Stephenson; Derek Raghavan; Robert Dreicer
Systems pathology and predicting outcome after radical prostatectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(24):3916-7.
2008: Donna E Hansel; Eric Swain; Robert Dreicer; Raymond R Tubbs
HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases.
American journal of clinical pathology 2008;130(2):274-81.
2008: Robert Dreicer
Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer.
Urologic oncology 2008;26(4):426-9.
2008: Saby George; Thomas E Hutson; Tarek Mekhail; Laura Wood; James Finke; Paul Elson; Robert Dreicer; Ronald M Bukowski
Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
Cancer chemotherapy and pharmacology 2008;62(2):347-54.
2008: Robert Dreicer; Hailun Li; Matthew M Cooney; George Wilding; Bruce J Roth
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
Cancer 2008;112(12):2671-5.
2008: Jorge A Garcia; Eric A Klein; Cristina Magi-Galluzzi; Paul Elson; Pierre Triozzi; Robert Dreicer
Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):3052-9.
2008: Nivedita Bhatta Dhar; J Stephen Jones; Alwyn M Reuther; Robert Dreicer; Steven C Campbell; Kamrooz Sanii; Eric A Klein
Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
BJU international 2008;101(8):969-72.
2008: Howard I Scher; Susan Halabi; Ian Tannock; Michael J Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia S Higano; Glenn J Bubley; Robert Dreicer; Daniel P Petrylak; Philip W Kantoff; Ethan Basch; W Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1148-59.
2008: Toni K Choueiri; Robert Dreicer; Alan Paciorek; Peter R Carroll; Badrinath R Konety
A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
The Journal of urology 2008;179(3):906-10; discussion 910.
2008: Ila Tamaskar; Ronald Bukowski; Paul Elson; A G Ioachimescu; Laura Wood; Robert Dreicer; Tarek Mekhail; J Garcia; Brian I Rini
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):265-8.
2008: Ila Tamaskar; Jorge A Garcia; Paul Elson; Laura Wood; Tarek Mekhail; Robert Dreicer; Brian I Rini; Ronald M Bukowski
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
The Journal of urology 2008;179(1):81-6; discussion 86.
2007: Deborah A Bradley; Rodney Dunn; David M Nanus; Walter Stadler; Robert Dreicer; Jonathan Rosenberg; David C Smith; Maha Hussain
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
Clinical genitourinary cancer 2007;5(7):460-3.
2007: Nikolaj Lagwinski; Anil Thomas; Andrew J Stephenson; Steven Campbell; Aaron P Hoschar; Ehab El-Gabry; Robert Dreicer; Donna E Hansel
Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases.
The American journal of surgical pathology 2007;31(12):1777-87.
2007: Tomasz M Beer; Celestia S Higano; Mansoor Saleh; Robert Dreicer; Gary Hudes; Joel Picus; Mark Rarick; Louis Fehrenbacher; Alison L Hannah
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
Investigational new drugs 2007;25(6):565-70.
2007: Lawrence H Einhorn; Mary J Brames; Robert Dreicer; Craig Nichols; Michael T Cullen; Joseph S Bubalo
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(11):1293-300.
2007: Cristina Magi-Galluzzi; Ming Zhou; Alwyn M Reuther; Robert Dreicer; Eric A Klein
Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Cancer 2007;110(6):1248-54.
2007: Robert Dreicer; Shuli Li; Judith Manola; Naomi B Haas; Bruce J Roth; George Wilding
Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group.
Cancer 2007;110(4):759-63.
2007: Sujith Kalmadi; Mellar Davis; Afshin Dowlati; S O'Keefe; M Cline-Burkhardt; Robert Pelley; Ernest C Borden; Robert Dreicer; Ronald Bukowski; Tarek Mekhail
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.
Investigational new drugs 2007;25(3):211-6.
2007: Adam S Kibel; Eli Rosenbaum; Michael W Kattan; Joel Picus; Robert Dreicer; Eric A Klein; Gurkamal S Chatta; Joel B Nelson; Robert S DiPaola; Bruce J Roth; Michael S Cookson; George Wilding; David F Jarrard; Tomasz M Beer; Christopher W Ryan; Daniel P Petrylak; Mitchell C Benson; Alan W Partin; Elizabeth Garrett-Mayer; Mario A Eisenberger
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
The Journal of urology 2007;177(5):1777-81.
2007: Timothy Gilligan; Robert Dreicer
The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis.
Seminars in oncology 2007;34(2):145-53.
2007: Robert Dreicer
Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors.
Current oncology reports 2007;9(2):120-3.
2007: Tomasz M Beer; Christopher W Ryan; Peter M Venner; Daniel P Petrylak; Gurkamal S Chatta; J Dean Ruether; Charles H Redfern; Louis Fehrenbacher; Mansoor N Saleh; David M Waterhouse; Michael A Carducci; Daniel Vicario; Robert Dreicer; Celestia S Higano; Frederick R Ahmann; Kim N Chi; W David Henner; Alan Arroyo; Fong W Clow
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):669-74.
2007: Robert Dreicer; Daniel P Petrylak; David B Agus; Iain Webb; Bruce Roth
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1208-15.
2007: Brian I Rini; Ila Tamaskar; Philip E Shaheen; Renee Salas; Jorge Garcia; Laura Wood; Sethu Reddy; Robert Dreicer; Ronald M Bukowski
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Journal of the National Cancer Institute 2007;99(1):81-3.
2007: Robert Dreicer
Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: current standards.
Urologic oncology 2007;25(1):72-5.
2007: Ena Segota; Tarek Mekhail; Thomas Olencki; Thomas E Hutson; Robert Dreicer; Brenda Wacker; Bruno Osterwalder; Paul Elson; Ming Zhou; Ronald M Bukowski
Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Urologic oncology 2007;25(1):46-52.
2006: Jorge A Garcia; Robert Dreicer
Systemic chemotherapy for advanced bladder cancer: update and controversies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(35):5545-51.
2006: Robert Dreicer
Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.
Clinical genitourinary cancer 2006;5 Suppl 1():S19-23.
2006: Toni K Choueiri; Robert Dreicer; Brian I Rini; Paul Elson; Jorge A Garcia; Snehal G Thakkar; Rachid Baz; Tarek Mekhail; Holly A Jinks; Ronald M Bukowski
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Cancer 2006;107(11):2609-16.
2006: Robert Dreicer
Chemotherapy for advanced prostate cancer: docetaxel and beyond.
Hematology/oncology clinics of North America 2006;20(4):935-46, x.
2006: Thomas Olencki; Sareena Malhi; Tarek Mekhail; Robert Dreicer; Paul Elson; Laura Wood; Ronald M Bukowski
Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.
Investigational new drugs 2006;24(4):321-6.
2006: Tomasz M Beer; Catherine M Tangen; Craig Nichols; Kim Margolin; Robert Dreicer; William T Stephenson; David I Quinn; Derek Raghavan; E David Crawford
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Cancer 2006;106(12):2624-9.
2006: Robert Gray; Judith Manola; Scott Saxman; John Wright; Janice Dutcher; Michael Atkins; Michael A Carducci; William A See; Christopher Sweeney; Glenn Liu; Mark Stein; Robert Dreicer; George Wilding; Robert S DiPaola
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):1966-9.
2005: John M Strother; Tomasz M Beer; Robert Dreicer
Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?
European journal of cancer (Oxford, England : 1990) 2005;41(6):954-64.
2005: Robert Dreicer; Eric A Klein; Paul Elson; David M Peereboom; Tatiana V Byzova; Edward F Plow
Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer.
Urologic oncology 2005;23(2):82-6.
2005: Jorge A Garcia; Robert Dreicer
Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies.
Nature clinical practice. Urology 2005;2(1):32-7.
2005: Sam S Chang; Mitchell C Benson; Steven C Campbell; Juanita Crook; Robert Dreicer; Christopher P Evans; craig hall; Celestia S Higano; W Kevin Kelly; Oliver Sartor; Joseph A Smith
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma.
Cancer 2005;103(1):11-21.
2004: Nancy Price; Robert Dreicer
Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Clinical prostate cancer 2004;3(3):141-3.
2004: Robert Dreicer; Cristina Magi-Galluzzi; Ming Zhou; Jason Rothaermel; Alwyn M Reuther; James Ulchaker; Craig D Zippe; Amr Fergany; Eric A Klein
Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
Urology 2004;63(6):1138-42.
2004: Mellar P Davis; Robert Dreicer; Declan Walsh; Ruth Lagman; Susan B LeGrand
Appetite and cancer-associated anorexia: a review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1510-7.
2004: Robert Dreicer; Judith Manola; Bruce J Roth; William A See; Steven Kuross; Martin J Edelman; Gary R Hudes; George Wilding
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Cancer 2004;100(8):1639-45.
2003: Louis Kantzavelos; Eric A Klein; Robert Dreicer
Paracolic recurrence of stage I seminoma.
Urology 2003;62(1):145.
2003: Robert Dreicer
Neoadjuvant chemotherapy for bladder cancer: current status.
Expert opinion on pharmacotherapy 2003;4(6):853-8.
2003: Robert Dreicer; Judith Manola; Daniel J Schneider; John F Schwerkoske; Christopher S George; Bruce J Roth; George Wilding
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Cancer 2003;97(11):2743-7.
2003: Robert Dreicer; Bruce Roth; George Wilding
Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group.
Cancer 2003;97(8 Suppl):2109-14.
2003: Thomas E Hutson; Luis Molto; Tarek Mekhail; Paul Elson; James Finke; Charles S Tannenbaum; Ernest C Borden; Robert Dreicer; Thomas Olencki; Ronald M Bukowski
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1354-60.
2003: Robert Dreicer; Michael A Carducci
E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels.
Reviews in urology 2003;5 Suppl 2():S35-41.
2003: Eric A Klein; Robert Dreicer
Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer.
Reviews in urology 2003;5 Suppl 2():S22-7.
2003: Robert Dreicer; Michael A Carducci
E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels.
Reviews in urology 2003;5 Suppl 3():S52-8.
2003: Eric A Klein; Robert Dreicer
Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer.
Reviews in urology 2003;5 Suppl 3():S22-7.
2003: Roland T Skeel; Jie Huang; Judith Manola; George Wilding; Robert Dreicer; Paul Walker; Franco Muggia; E David Crawford; Janice P Dutcher; Patrick J Loehrer
A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
Cancer investigation 2003;21(1):41-6.
2002: John Thomas; Michael Aleman; Robert Dreicer; Eric A Klein
Management of stage I nonseminomatous germ-cell tumors.
Seminars in urologic oncology 2002;20(4):220-6.
2002: Bruce J Roth; Judith Manola; Robert Dreicer; David Graham; George Wilding
Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group.
Investigational new drugs 2002;20(4):425-9.
2002: Aaron J Milbank; Robert Dreicer; Eric A Klein
Hormonal therapy for prostate cancer: primum non nocere.
Urology 2002;60(5):738-41.
2002: Mellar P Davis; Robert Dreicer
Revisiting truth and consequences: what to do when the patient doesn't want to know.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(21):4403-4.
2002: David J Vaughn; Judith Manola; Robert Dreicer; William A See; Ralph Levitt; George Wilding
Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group.
Cancer 2002;95(5):1022-7.
2002: Robert Dreicer
Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy.
Cancer treatment reviews 2002;28(4):189-94.
2002: John Thomas; Manjula Gupta; Ying Grasso; Chandana A Reddy; Warren D W Heston; Craig D Zippe; Robert Dreicer; Patrick A Kupelian; Jennifer Brainard; Howard S Levin; Eric A Klein
Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3213-8.
2002: Ashraf S Mahmoud-Ahmed; John H Suh; Patrick A Kupelian; Eric A Klein; David M Peereboom; Robert Dreicer; Gene H Barnett
Brain metastases from bladder carcinoma: presentation, treatment and survival.
The Journal of urology 2002;167(6):2419-22.
2001: Robert Dreicer
Locally advanced and metastatic bladder cancer.
Current treatment options in oncology 2001;2(5):431-6.
2001: E A Klein; P A Kupelian; Robert Dreicer; David M Peereboom; C Zippe
Locally advanced prostate cancer.
Current treatment options in oncology 2001;2(5):403-11.
2001: Robert Dreicer; E A Klein
Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer.
Seminars in oncology 2001;28(4 Suppl 15):45-8.
2001: Robert Dreicer
Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer.
Seminars in urologic oncology 2001;19(3):180-5.
2001: P E Clark; David M Peereboom; Robert Dreicer; Howard S Levin; Sarah B Clark; Eric A Klein
Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
Urology 2001;57(2):281-5.
2001: Robert Dreicer; William A See; E A Klein
Phase II trial of GM-CSF in advanced prostate cancer.
Investigational new drugs 2001;19(3):261-5.
2000: Ernest C Borden; Daniel J Lindner; Robert Dreicer; M Hussein; David M Peereboom
Second-generation interferons for cancer: clinical targets.
Seminars in cancer biology 2000;10(2):125-44.
2000: Robert Dreicer; Judith Manola; Bruce J Roth; M B Cohen; A K Hatfield; George Wilding
Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):1058-61.
1999: Robert Dreicer; David C Smith; R D Williams; William A See
Phase II trial of suramin in patients with metastatic renal cell carcinoma.
Investigational new drugs 1999;17(2):183-6.
1998: Robert Dreicer; TA Lallas; J K Joyce; B Anderson; Joel I Sorosky; Richard E Buller
Vinblastine, ifosfamide, gallium nitrate, and filgrastim in platinum- and paclitaxel-resistant ovarian cancer: a phase II study.
American journal of clinical oncology 1998;21(3):287-90.
1998: Alan B Sandler; S Fox; T Meyers; A Christou; G Weber; R Gonin; Patrick J Loehrer; Lawrence H Einhorn; Robert Dreicer
Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial.
American journal of clinical oncology 1998;21(2):180-4.
1997: William A See; Robert Dreicer; Paula K Forest; C Riggs
Continuous infusion, intravesical doxorubicin for the treatment of regionally advanced bladder cancer: a phase I-II trial.
American journal of clinical oncology 1997;20(4):331-7.
1997: Robert Dreicer; Kathleen J Propert; T Kuzel; J M Kirkwood; P J O'Dwyer; Patrick J Loehrer
A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study.
American journal of clinical oncology 1997;20(3):251-3.
1997: Robert Dreicer; S S Galbraith; Charles S Davis; William A See
Surgical resection of metastatic renal cell carcinoma: The University of Iowa experience.
Urologic oncology 1997;3(3):99-101.
1997: Robert Dreicer; Mark W Karwal; G Midence; Charles S Davis; Mary D Nettleman
The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin-based chemotherapy: a reassessment.
American journal of clinical oncology 1997;20(2):132-7.
1997: R S Witte; P Elson; B Bono; R Knop; R R Richardson; Robert Dreicer; Patrick J Loehrer
Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):589-93.
1997: Robert Dreicer
Metastatic prostate cancer: assessment of response to systemic therapy.
Seminars in urologic oncology 1997;15(1):28-32.
1997: Robert Dreicer; John D Kemp; L D Stegink; T Cardillo; Charles S Davis; Paula K Forest; William A See
A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer.
Cancer investigation 1997;15(4):311-7.
1997: Robert Dreicer; Kathleen J Propert; B J Roth; L H Einhorn; Patrick J Loehrer
Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892).
Cancer 1997;79(1):110-4.
1996: Robert Dreicer; D M Gustin; William A See; Richard D Williams
Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy.
The Journal of urology 1996;156(5):1606-8.
1996: William A See; Robert Dreicer; J A Wheeler; P K Forest; S Loening
Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial.
Cancer 1996;77(5):924-7.
1996: Robert Dreicer; C S Cooper; Richard D Williams
Management of prostate and bladder cancer in the elderly.
The Urologic clinics of North America 1996;23(1):87-97.
1996: William A See; J F Laurenzo; Robert Dreicer; Henry T Hoffman
Incidence and management of testicular carcinoma metastatic to the neck.
The Journal of urology 1996;155(2):590-2.
1996: G H Clamon; C E Riggs; Robert Dreicer; Raymond J Hohl
Phase II trial of edatrexate in patients with metastatic colorectal cancer.
Investigational new drugs 1996;13(4):359-61.
1994: D Kahn; Richard D Williams; D W Seldin; John A Libertino; M Hirschhorn; Robert Dreicer; G J Weiner; D Bushnell; J Gulfo
Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence.
The Journal of urology 1994;152(5 Pt 1):1490-5.
1994: Robert Dreicer; P K Forest; Richard D Williams
Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer.
Urology 1994;44(3):377-80.
1994: Jay I Sandlow; M B Cohen; Robert A Robinson; Robert Dreicer; Richard D Williams
DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer.
Urology 1994;43(6):787-91.
1994: Robert Dreicer; D Gesme
Cancer pain management: 'inadequate'.
Iowa medicine : journal of the Iowa Medical Society 1994;84(6):252-4.
1993: Robert Dreicer; T A Kollmorgen; R F Smith; Richard D Williams
Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup.
The Journal of urology 1993;150(3):849-52.
1992: Robert Dreicer; J Donovan; Jo Ann Benda; J Lund; R L Degowin
Paraneoplastic erythrocytosis in a young adult with an erythropoietin-producing Wilms' tumor.
The American journal of medicine 1992;93(2):229-30.
1992: Robert Dreicer; G Wilding
Steroid hormone agonists and antagonists in the treatment of cancer.
Cancer investigation 1992;10(1):27-41.
1991: Robert Dreicer; William A See; R Williams
Controversies in urologic oncology.
Iowa medicine : journal of the Iowa Medical Society 1991;81(8):343-5.